Drug Information

Drug (ID: DG01893) and It's Reported Resistant Information

• Name: Peginterferon alfa-2a
• Synonyms: Peginterferon alfa-2a
• Indication:
  In total 1 Indication(s)
  Hairy cell leukaemia [ICD-11: 2A82]; Phase 2; [1]
• Target: Interferon-alpha 2 (IFNA2); IFNA2_HUMAN; [1]

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Chronic myeloid leukemia [ICD-11: 2A20]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Tyrosine-protein kinase JAK2 (JAK3) [1]

• Molecule Alteration: Missense mutation; p.V617F (c.1849G>T)
• Sensitive Disease: Chronic myeloid leukemia [ICD-11: 2A20.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Bone marrow; N.A.
• Mechanism Description: The missense mutation p.V617F (c.1849G>T) in gene JAK2 cause the sensitivity of Peginterferon alfa-2a by unusual activation of pro-survival pathway

References

• Ref 1: High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2aBlood. 2006 Sep 15;108(6):2037-40. doi: 10.1182/blood-2006-03-009860. Epub 2006 May 18.